SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06500.0%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mimbari who wrote (12185)7/5/2013 3:18:57 PM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

  Read Replies (1) of 13111
 
Beyond the difficulty in replicating poorly designed pre-clinical studies overall, wouldn't it be hard to conclude who was doing the study right and who was doing the study wrong when two groups don't agree? Besides, if you are claiming that commercial groups always get their studies right, why the delay in publishing the PV-10 PII trial data, or the pre-clinical "PV-10 doesn't harm healthy cells" story? Rather judgmental of you to jump on one side of the story, unless you are....

Lets do this another way, name a drug approved for use in the US that did not have significant publications during their pre-clinical or as a result of their PI, PII or PIII trials.....just one will do
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News